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Abstract: Intravesical application of an anti-inflammatory drug is an efficient strategy for 
acute cystitis therapy. Quercetin (QU) is a potent anti-inflammatory agent; however, its poor 
water solubility restricts its clinical application. In an attempt to improve water solubility of QU, 
  biodegradable monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) (MPEG-PCL) micelles 
were used to encapsulate QU by self-assembly methods, creating QU/MPEG-PCL micelles. 
These QU/MPEG-PCL micelles with DL of 7% had a mean particle size of ∼34 nm, and could 
release QU for an extended period in vitro. The in vivo study indicated that intravesical appli-
cation of MPEG-PCL micelles did not induce any toxicity to the bladder, and could efficiently 
deliver cargo to the bladder. Moreover, the therapeutic efficiency of intravesical administration 
of QU/MPEG-PCL micelles on acute cystitis was evaluated in vivo. Results indicated that QU/
MPEG-PCL micelle treatment efficiently reduced the edema and inflammatory cell infiltration 
of the bladder in an Escherichia coli-induced acute cystitis model. These data suggested that 
MPEG-PCL micelle was a candidate intravesical drug carrier, and QU/MPEG-PCL micelles 
may have potential application in acute cystitis therapy.
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Introduction
Urinary tract infections (UTIs) are one of the most common bacterial infections, and 
Escherichia coli bacteria are the main cause of UTI.1–4 Bacterial infection of the blad-
der always leads to acute cystitis. Patients with acute cystitis account for 95% of all 
visits to physicians for UTIs. Commonly, patients with acute cystitis have symptoms 
of dysuria and increased frequency and urgency of urination, which greatly affect their 
quality of life.5 In the past decades, great efforts have been made to develop efficient 
therapeutics to treat acute cystitis. Despite many patients with acute cystitis having 
benefited from these efforts,6 acute cystitis therapy still poses great challenges.
Currently, acute cystitis is commonly treated by systemic application of antibi-
otics and anti-inflammation agents. However, only a small amount of systemically 
administered drugs can reach the bladder. Intravesical administration means directly 
instilling the drug solution into the bladder through a urethral catheter, ensuring maxi-
mum delivery of active ingredients to the bladder.7–10 In addition, intravesical drug 
administration has other potential benefits such as avoiding the first-pass metabolism. 
Compared with systemic drug administration, intravesical drug administration, as a 
local drug delivery method, can increase drug utilization and reduce systemic toxicity 
and side effects. Thus, intravesical application of therapeutics attracts some attention 
for cystitis therapy.
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Quercetin (QU; 3,3,4,5,7-pentahydroxyflavone) is one of 
the most abundant flavonoids found in plants with biological 
effects; its molecular structure is presented in Figure 1A.11,12 
To the authors’ knowledge, QU has a wide range of bio-
logical properties, including anti-viral,13 anti-inflammatory,14 
anti-oxidative,15 and anti-tumor activities.16,17 In recent 
years, the anti-inflammatory effect of QU has been well 
recognized,18,19 suggesting that QU as an anti-inflammatory 
drug has promising clinical application. Recently, it was 
found that QU can be used to prevent interstitial cystitis.20 
The authors presumed that QU might have potential appli-
cation in intravesical therapy of acute cystitis, and set out 
to prove this hypothesis in this work. However, QU is water 
insoluble, and developing an aqueous formulation for QU 
remains difficult, greatly restricting the clinical application 
of QU. Therefore, it is necessary to develop an aqueous 
QU formulation as well as study the application of QU in 
depth in vivo.
Nanotechnology provides a novel platform for delivery of 
lipophilic drugs.21,22 Encapsulation of hydrophobic drugs into 
nanoparticles can render the drug completely dispersible in 
solution. Biodegradable polymeric nanoparticles are regarded 
as excellent candidates for drug-delivery systems.23–25 Poly(ε-
caprolactone) (PCL)/poly(ethylene glycol) (PEG) copoly-
mers are biodegradable, amphiphilic, and easy to produce, 
showing promising applications in drug-delivery systems.26,27 
Monomethoxy PEG (MPEG)-PCL is a diblock PCL/PEG 
copolymer; its molecular structure is shown in Figure 1B. 
The authors have previously used MPEG-PCL micelles to 
deliver curcumin, creating a novel curcumin formulation with 
potential application in colon cancer therapy.28 In an attempt 
to develop an aqueous formulation for QU, MPEG-PCL 
micelles were used to encapsulate QU, creating QU/MPEG-
PCL micelles. The effect of intravesical application of QU/
MPEG-PCL micelles on acute cystitis was then   evaluated. 
These results suggest that QU/MPEG-PCL micelles are a new 
formulation of QU, with potential applications in bacterial 
cystitis therapy.
Materials and methods
Materials
Escherichia coli DH5α was saved in the laboratory and was 
cultured at 37°C on solid Luria-Bertani (LB) medium or in 
liquid LB medium. QU was purchased from Sigma-Aldrich 
(St Louis, MO). MPEG-PCL diblock copolymer with a 
designed molecular weight of 4000 was synthesized accord-
ing to previous reports.27,28
Female BALB/c mice (8–10 weeks old) were purchased 
from the Laboratory Animal Center of Sichuan University 
(Chengdu, China). All studies involving mice were approved 
by the Institute’s Animal Care and Use Committee.
Preparation of QU/MPEG-PCL 
micelles
QU/MPEG-PCL micelles were prepared by a self-assembly 
method. Briefly, QU (7 mg) and MPEG-PCL diblock 
c  opolymer (93 mg) were co-dissolved in 6 mL of organic 
solvent (dichloromethane [DCM] : methanol = 2:1), fol-
lowed by evaporation under reduced pressure in a rotary 
evaporator at 55°C. Normal saline (NS) (5 mL) was then 
added into the polymer and drug mixture, allowing the 
self-assembly of MPEG-PCL and QU, creating core-shell 
structured QU/MPEG-PCL micelles with core-encapsulated 
QU. The QU/MPEGPCL micelle solution was filtered using 
a syringe filter (pore size: 220 nm) (Millex-LG, Millipore Co, 
  Billerica, MA) to remove the impurity and bacteria. Finally, 
the prepared QU/MPEG-PCL micelles were lyophilized and 
stored at 4°C.
Characterization of QU/MPEG-PCL 
micelles
The particle size and zeta potential of QU/MPEG-PCL 
micelles were determined by dynamic light scattering (DLS) 
(Malvern Nano-ZS 90; Malvern Instruments, Malvern, UK). 
The temperature was kept at 25°C during the measuring 
process. All results were the mean of three test runs.
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Figure 1 Molecular structure of (A) quercetin and (B) monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) copolymer.
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The morphology of QU/MPEG-PCL micelles was 
observed under a transmission electron microscope 
(H-6009IV; Hitachi, Tokyo, Japan): micelles were diluted 
with distilled water and placed on a copper grid covered 
with nitrocellulose. Samples were negatively stained with 
phosphotungstic acid and dried at room temperature.
The concentration of QU was determined by high-
 performance liquid chromatography (HPLC) (Waters   Alliance 
2695; Waters, Milford, MA). The solvent delivery system 
was equipped with a column heater and a plus autosampler. 
Detection was carried out on a Waters 2996 detector. Chro-
matographic separations were performed on a reversed phase 
C18 column (4.6 × 150 mm-5µm, Sunfire Analysis column), 
with the column temperature kept at 35°C. Methanol–water 
(70/30, v/v) was used as eluent at a flow rate of 1 mL⋅min−1.
Drug loading (DL) and encapsulation efficiency (EE) 
of QU/MPEG-PCL micelles were determined as follows: 
Briefly, 10 mg of lyophilized QU/MPEG-PCL micelles were 
dissolved in 0.1 mL DCM and diluted with methanol. The 
amount of QU in the solution was determined by HPLC. 
Finally, the DL and EE of QU/MPEG-PCL micelles were 
calculated according to equations (1) and (2):
  DL =
+
Drug
polymer Drug
×100%  (1)
  EE
Experimental drug loading
Theoretical drug loading
=× 100%  (2)
In vitro drug release
To determine the release kinetics of QU from QU/MPEG-PCL 
micelles, 0.5 mL of QU/MPEG-PCL micelle solution was 
placed in a dialysis bag (molecular weight cutoff, 3.5 kDa). 
Dialysis bags were incubated in 30 mL of phosphate buffer 
solution (pH 7.4) containing Tween® 80 (Sigma-Aldrich) 
(0.5% w/w) at 37°C with gentle shaking. At predetermined 
time points, the incubation medium was replaced with fresh 
incubation medium. The amount of released drug in the 
incubation medium was quantified by determining absor-
bance at 370 nm using HPLC. This study was repeated three 
times, and the result was expressed as mean value ± standard 
deviation (SD).
Analysis of the acute toxicity  
of MPEG-PCL micelles
Fifteen female BALB/c mice (8 weeks old) were used to 
evaluate the acute toxicity of MPEG-PCL micelles after 
intravesical application. These mice were divided into three 
groups (five mice per group): one group as the control did not 
receive any treatment, while the other two groups were treated 
with NS or MPEG-PCL micelles (50 mg/mL × 0.1 mL), 
respectively. Twenty-four hours after perfusion, all mice 
were killed by cervical vertebra dislocation. Bladders were 
immediately removed, weighted, and fixed in neutral buffer 
formalin (10%). The bladders were then paraffin-embedded, 
and sections were stained with hematoxylin and eosin (H&E). 
Moreover, the heart, liver, spleen, kidney, and lung of each 
mouse were also examined by H&E staining.
Distribution in vivo
Thirty-three female BALB/c mice (8 weeks old) were used to 
evaluate the distribution of MPEG-PCL micelles. These mice 
were divided into eleven groups (three mice per group).
Due to its specific fluorescence spectrum, coumarin-6 
was used as a model drug to evaluate the capacity of MPEG-
PCL micelles to deliver cargo to bladder. Coumarin-6/
MPEG-PCL micelles were prepared by a rotary evapora-
tion method. Briefly, coumarin-6 (0.5 mg) and MPEG-PCL 
diblock copolymer (99.5 mg) were co-dissolved in 6 mL of 
DCM and evaporated to dryness under reduced pressure in 
a rotary evaporator. The dried films were hydrated in 5 mL 
of 0.9% NS.
The effect of the administration method on the bladder 
drug deposition of MPEG-PCL micelle-encapsulated drugs 
was studied in vivo. Coumarin-6/MPEG-PCL micelles 
(0.1 mL) were intravenously or intravesically administered 
into 8-week-old female BALB/c mice. At different time points 
(0.5, 1, 2, 4, and 6 hours) after administration, mice were killed 
by cervical vertebra dislocation, and their bladders were imme-
diately harvested and examined by the curmarin-6-associated 
green fluorescence under a fluorescence light box (Lightools 
Research, Encinitas, CA). Moreover, to study the effect of 
administration method on the distribution of MPEG-PCL 
micelle-encapsulated drugs in vivo, the heart, liver, spleen, 
lung, and kidney of the mice were also harvested 2 hours after 
treatment and examined by the curmarin-6-associated green 
fluorescence under live image analysis instrument (Lightools 
Research). These experiments were repeated three times, and 
representative images were obtained.
Establishment of acute cystitis model
The acute cystitis model was established by intravesical 
application of bacterial strain E. coli DH5α into 8-week-
old female BALB/c mice by transurethral catheterization as 
previously described.29 E. coli DH5α was cultured at 37°C 
in 5 mL LB for 18 hours, then centrifuged for 1 minute at 
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10,000 rpm, washed with phosphate-buffered saline (PBS) 
three times and diluted to 2 × 108 CFU/mL. 50 µL of this 
suspension was used to infect each mouse with inoculums 
of ∼1 × 107 CFU.
Treatment of acute cystitis  
by QU/MPEG-PCL micelles
Twenty 8-week-old female BALB/c mice were infected with 
E. coli DH5α (∼1 × 107 CFU per mouse). Twenty-four hours 
later, the mice were divided into four groups. One group 
as the control did not receive any treatment, and the other 
groups were intravesically treated with NS (0.9%), MPEG-
PCL micelle saline solution (700 µg/mL × 100 uL) and QU/
MPEG-PCL micelle saline solution (QU: 50 µg/mL × 100 uL), 
respectively. After 24 hours of treatment, the mice were killed 
by cervical vertebra dislocation. The bladder of each mouse 
was harvested and fixed with 10% buffered formaldehyde. 
The bladders were then embedded in paraffin, and at least 
four cross sections (5 µm thick) were taken from each blad-
der, followed by H&E staining.
Statistical analysis
Data were expressed as the mean ± SD. Statistical analysis 
was performed with one-way analysis of variance using SPSS 
Statistics (version 19.0.1; IBM Corporation, Somers, NY) 
software. P values less than 0.05 were considered to be sta-
tistically significant.
Results
Preparation and characterization  
of Qu/MPEG-PCL micelles
In an attempt to develop an aqueous formulation for QU, 
biodegradable MPEG-PCL micelles were used to encapsu-
late QU. QU/MPEG-PCL micelles were prepared through 
a   self-assembly method, as schematically presented in 
Figure 2. First, MPEG-PCL copolymer and QU were co-
dissolved in a DCM and methanol mixture. Then, the organic 
solvent was evaporated under reduced pressure in a rotary 
evaporator, forming an MPEG-PCL and QU mixture. Finally, 
NS was added to the mixture, allowing the self-assembly of 
MPEG-PCL and QU in water. In the structure of MPEG-PCL, 
PEG is the hydrophilic segment, and PCL is the hydrophobic 
segment; thus, MPEG-PCL micelles always have a core-shell 
structure, with a PCL core and a PEG shell. The self-assembly 
of MPEG-PCL and QU created core-shell QU/MPEG-PCL 
micelles with core-encapsulated QU.
The QU/MPEG-PCL micelles were characterized in detail. 
The QU/MPEG-PCL micelles had DL and EE of 6.9% and 
98.1%, respectively. In Figure 3A, the particle size distribu-
tion spectrum of freshly prepared QU/MPEG-PCL micelles 
are presented. It was indicated that QU/MPEG-PCL micelles 
had a very narrow particle size distribution (polydispersity 
index [PDI] = 0.12), with a mean particle size of 34.1 ± 1.2 nm 
(determined by DLS). The zeta potential spectrum of QU/
MPEG-PCL micelles is presented in Figure 3B; QU/MPEG-
PCL micelles had a zeta potential of −0.269 mV . Moreover, 
the morphology of QU/MPEG-PCL micelles was studied by 
transmission electron microscopy (TEM), and the result is 
shown in Figure 3C. According to the TEM image, QU/MPEG-
PCL micelles were spherical with a mean diameter of ∼23 nm. 
TEM determined the size of dry particles, while the DLS 
determined the hydrodynamic diameter of particles in water. 
Because amphiphilic block polymeric micelles always have a 
loose structure in water, the particle size determined by DLS 
was always slightly larger than that determined by TEM.
One of the major purposes of the encapsulation 
of  QU  in  MPEG-PCL  micelles  was  to  make  QU 
  completely d  ispersible in aqueous media. The appearance 
PCL PEG
Self-assembly
QU + MPEG-PCL QU/MPEG-PCL micelle
QU
Figure 2 Preparation of QU-loaded MPEG-PCL nanoparticles. MPEG-PCL and QU were co-dissolved in organic solvent, followed by evaporation to dryness under reduced 
pressure in a rotary evaporator, creating QU and MPEG-PCL mixture (QU + MPEG-PCL).
Notes: The QU and MPEG-PCL mixture was then hydrated in 0.9% normal saline, allowing QU and MPEG-PCL to self-assemble into QU/MPEG-PCL micelles. This micelle 
has a core-shell structure (hydrophilic PEG shell and hydrophobic PCL core) with core-encapsulated QU.
Abbreviations: MPEG, monomethoxy poly(ethylene glycol); PCL, poly(ε-caprolactone); QU, quercetin.
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of QU/MPEG-PCL micelle aqueous solution is shown 
in   Figure 3D. QU cannot be dissolved in pure water, as 
confirmed by the   observation of a turbid yellow slurry. 
In contrast, QU/MPEG-PCL micelle solution with an 
equivalent quantity of QU was transparent, indicating full 
dispersibility of QU in water.
The release profile of QU/MPEG-PCL micelles in vitro 
was studied using a dialysis method. As shown in Figure 4, 
QU was released from QU/MPEG-PCL micelles over an 
extended period.
Analysis of toxicity  
of MPEG-PCL micelles
In this work, the authors attempted to treat acute cystitis by 
intravesical application of MPEG-PCL micelle-encapsulated 
QU. Thus, the toxicity of intravesically applied MPEG-PCL 
micelles was evaluated before treatment experiments. As 
shown in Figure 5A, intravesical   application of MPEG-
PCL micelles (50 mg/mL × 0.1 mL) did not significantly 
induce bladder weight change (control: 16.604 ± 0.739 mg; 
NS: 17.032 ± 1.846 mg; MPEG-PCL: 16.874 ± 0.780 mg), 
which implied that the intravesical application of MPEG-
PCL micelles did not significantly induce bladder edema. 
Moreover, pathological section of bladder in each treat-
ment group is shown in Figure 5B. We found that intravesi-
cal application of MPEG-PCL micelles did not induce any 
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Figure 3 Characterization of QU/MPEG-PCL micelles: (A) size distribution spectrum of QU/MPEG-PCL micelles; (B) zeta potential spectrum of MPEG-PCL micelles; 
(C) transmission electron microscopy image of QU/MPEG-PCL micelles; (D) the encapsulation of QU in MPEG-PCL/QU nanoparticles renders QU completely dispersible 
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Abbreviations: MPEG, monomethoxy poly(ethylene glycol); PCL, poly(ε-caprolactone); QU, quercetin.
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pathological changes to the bladder. Meanwhile, intravesical 
application of MPEG-PCL micelles did not cause any toxicity 
to the heart, liver, spleen, lung, or kidney (data not shown). 
These results suggest that MPEG-PCL micelles may be used 
as drug carriers for intravesical drug application.
Distribution in vivo
The tissue distribution of MPEG-PCL micelle-encapsulated 
drug after intravenous or intravesical application was   studied. 
Figure 6A shows that green fluorescence appeared in the 
heart, lung, liver, and kidney 2 hours after intravenous 
injection, implying drug deposition in these tissues. How-
ever, very little green fluorescence appeared in the heart, 
lung, liver, kidney, and spleen after intravesical administra-
tion of courmarin-6/MPEG-PCL, suggesting that little drug 
can reach these tissues after intravesical administration. 
Thus, for bladder diseases therapy, intravesical application 
of therapeutics may cause lower systemic toxicity compared 
with intravenous application.
The efficiency of MPEG-PCL micelles delivering cargo 
to bladder was studied after intravenous or intravesical 
application (see Figure 6B). With intravesical application 
of courmarin-6/MPEG-PCL micelles, the bladders ema-
nated strong courmarin-6-associated fluorescence, implying 
the high drug deposition in the bladder. With intravenous 
application of courmarin-6/MPEG-PCL micelles, the blad-
ders only had slight green fluorescence, suggesting the low 
efficiency of delivering cargo to bladder. Meanwhile, the 
residence time of green fluorescence in the bladder with 
intravesical administration was obviously longer than that 
with intravenous application. Thus, for bladder diseases 
therapy, intravesical application of therapeutics may induce 
higher efficiency of delivering cargos to bladder compared 
with intravenous application.
Treatment of acute cystitis
The anti-inflammatory effect of MPEG-PCL micelle-encap-
sulated QU in the acute cystitis model was assessed. As shown 
in Figure 7A, the weight of bladders in the QU/MPEG-PCL 
micelle treatment group was 20.50 ± 1.44 mg, while the 
weight of bladders in the NS and empty MPEG-PCL micelle 
treatment group were 43.26 ± 1.42 mg and 41.42 ± 1.68 mg, 
respectively. Compared with NS treatment, QU/MPEG-PCL 
micelle treatment significantly reduced the weight of bladders 
with severe inflammation (P , 0.05), but empty MPEG-PCL 
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micelle treatment did not reduce the weight of bladders 
with severe inflammation (P . 0.05). This indicated that 
QU-loaded MPEG-PCL micelles effectively inhibited devel-
opment of acute cystitis compared with NS, while empty 
MPEG-PCL micelles did not show any anti-inflammatory 
activity on acute cystitis.
In Figure 7B, the appearance of the bladders in each treat-
ment group is presented. The bladder in the QU/MPEG-PCL 
group was obviously smaller than that in the NS group, while 
the bladder in the empty MPEG-PCL micelle group was as large 
as that in the NS group. This indicated that the edema of the 
bladder efficiently lessened with QU/MPEG-PCL treatment.
In Figure 7C, the pathological section of bladders in each 
treatment group is provided. that the figure shows that the 
bladders in both the empty MPEG-PCL micelle group and 
the NS group had severe edema and lots of inflammatory cell 
infiltration. However, in the QU/MPEG-PCL treatment group, 
the bladder did not have obvious edema and inflammatory cell 
infiltration. These results suggest that the QU/MPEG-PCL 
micelles have promising application in acute cystitis therapy.
Discussion
In this work, QU/MPEG-PCL micelles of uniform size (size, 
34.1 nm; PDI, 0.12) and high encapsulation rate (.98%) 
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successfully solved the problem of poor water solubility of 
QU (Figure 3). These QU/MPEG-PCL micelles could slowly 
release QU in vitro (Figure 4). Moreover, QU/MPEG-PCL 
micelles were used to treat acute cystitis, and it was found 
that intravesical application of MPEG-PCL micelles did not 
induce any toxicity to the bladder, and intravesical admin-
istration of QU/MPEG-PCL micelles efficiently reduced 
the inflammation of the bladder with E. coli-induced acute 
cystitis.
Patients with acute cystitis always have symptoms of 
dysuria and increased frequency and urgency of urination, 
which seriously affect their quality of life. The incidence 
of acute cystitis is high, and the course of acute cystitis is 
urgent. If acute cystitis cannot be treated in a timely manner, 
it will be transformed into chronic cystitis. It can also be 
transformed into cystitis glandularis, and finally into bladder 
cancer. It can also induce nephritis. Therefore, timely treat-
ment of acute cystitis is necessary. Acute cystitis therapy has 
received special attention in the past decades.30 The urinary 
bladder is an ideal organ for regional therapy. The urethra 
provides easy access of the therapeutic agents to the bladder. 
Moreover, this current work has proved that intravesical drug 
application can more efficiently deliver drugs to the blad-
der, with minimal side effects compared with intravenous 
a  pplication. Therefore, intravesical application of drugs may 
be an acceptable strategy for acute cystitis therapy. However, 
this method may have a weakness: intravesical instillation 
of drugs into the bladder is inconvenient.
Nanotechnology has a wide application in medicine, with 
the goal of resolving some medical challenges. One of the 
most important applications of nanotechnology in medicine 
is using nanoparticles to deliver hydrophobic drugs to create 
aqueous formulations for these water soluble-poor drugs. QU 
has great prospects in the treatment of inflammation,31 but it is 
limited in its medical application due to poor water solubility. 
To address this challenge, the use of liposomes to encapsulate 
QU has been described.32 Recently, MPEG-PCL micelles were 
used to load curcumin and honokiol,28,33 successfully solving 
their water solubility. In this paper, MPEG-PCL micelles were 
used to encapsulate QU with the goal of improving the water 
solubility of QU and creating a novel formulation for QU. 
Previously, MPEG-PCL micelles had been used to deliver 
drugs followed by intravenous, subcutaneous, intraperito-
neal, or intratumoral application. In this work, MPEG-PCL 
micelles were used to deliver drugs to the bladder by intra-
vesical application. The results suggested that intravesical 
application of MPEG-PCL micelle-encapsulated hydrophobic 
drugs can efficiently deliver cargo to the bladder.
Application of anti-inflammation agents is a commonly 
used protocol for acute cystitis therapy. QU is a well recog-
nized anti-inflammation agent.31 In this paper, QU was used 
to treat acute cystitis. Results indicated that QU/MPEG-PCL 
micelle treatment can efficiently reduce the edema and inflam-
matory cell infiltration of the bladder in an E. coli-induced 
acute cystitis model. These data proved the hypothesis that 
QU had potential application in acute cystitis therapy. To the 
authors’ knowledge, this work may be the first attempt to reveal 
the potential application of QU in acute cystitis therapy.
Overall, nanotechnology provides a novel method for 
improving the water solubility of QU. Intravesical applica-
tion of MPEG-PCL micelle-encapsulated QU has potential 
application in acute cystitis therapy.
Conclusion
In this paper, the nanoassemblies of QU and MPEG-PCL 
were studied, creating a novel QU/MPEG-PCL micelle, 
which is a new and interesting formulation of QU. MPEG-
PCL micelles may be a safe and efficient intravesical 
drug-delivery system for hydrophobic drugs. Intravesical 
administration of MPEG-PCL micelle-encapsulated QU can 
efficiently reduce the edema and inflammatory cell infiltra-
tion of bladders with acute cystitis, showing great potential 
in acute cystitis therapy.
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